Search

Your search keyword '"di Marco, Vito"' showing total 773 results
Start Over Author "di Marco, Vito"
773 results on '"di Marco, Vito"'

153. Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study

Author

Cammà, Calogero, Di Marco, Vito, Orlando, Ambrogio, Sandonato, Luigi, Casaril, Andrea, Parisi, Piero, Alizzi, Silvia, Sciarrino, Elio, Virdone, Roberto, Pardo, Salvatore, Di Bona, Danilo, Licata, Anna, Latteri, Federica, Cabibbo, Giuseppe, Montalto, Giuseppe, Latteri, Mario Adelfio, Nicoli, Nicola, Craxì, Antonio, and Unità Interdipartimentale Neoplasie Epatiche (U.I.N.E) Group

Published
2005
Full Text
View/download PDF

154. Random Forest Clustering Identifies Three Subgroups of β-Thalassemia with Distinct Clinical Severity.

Author

Vitrano, Angela, Musallam, Khaled M., Meloni, Antonella, Pollina, Sebastiano Addario, Karimi, Mehran, El-Beshlawy, Amal, Hajipour, Mahmoud, Di Marco, Vito, Ansari, Saqib Hussain, Filosa, Aldo, Ricchi, Paolo, Ceci, Adriana, Daar, Shahina, Vlachaki, Efthymia, Singer, Sylvia Titi, Naserullah, Zaki A., Pepe, Alessia, Scondotto, Salvatore, Dardanoni, Gabriella, and Bonifazi, Fedele

Subjects
RANDOM forest algorithms, IRON overload, IRON, ERROR rates, CAUSES of death, HEART failure
Abstract

In this work, we aimed to establish subgroups of clinical severity in a global cohort of β-thalassemia through unsupervised random forest (RF) clustering. We used a large global dataset of 7910 β-thalassemia patients and evaluated 19 indicators of phenotype severity (IPhS) to determine their contribution and relatedness in grouping β-thalassemia patients into clusters using RF analysis. RF clustering suggested that three clusters with minimal overlapping exist (classification error rate: 4.3%), and six important IPhS were identified: the current age of the patient, the mean serum ferritin level, the age at diagnosis, the age at first transfusion, the age at first iron chelation, and the number of complications. Cluster 3 represented patients with early initiation of transfusion and iron chelation, considerable iron overload, and early mortality from heart failure. Patients in Cluster 2 had lower serum ferritin levels, although they had a higher number of complications manifesting overtime. Patients in Cluster 1 represented a subgroup with delayed or absent transfusion and iron chelation, but with a high morbidity rate. Hepatic disease and cancer were dominant causes of death in patients in Cluster 1 and 2. Our findings established that patients with β-thalassemia can be clustered into three groups based on six parameters of phenotype severity. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

157. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites

Author

Caraceni, Paolo, Tufoni, Manuel, Zaccherini, Giacomo, Riggio, Oliviero, Angeli, Paolo, Alessandria, Carlo, Neri, Sergio, Foschi, Francesco G, Levantesi, Fabio, Airoldi, Aldo, Simone, Loredana, Svegliati-Baroni, Gianluca, Fagiuoli, Stefano, Laffi, Giacomo, Cozzolongo, Raffaele, Di Marco, Vito, Sangiovanni, Vincenzo, Morisco, Filomena, Toniutto, Pierluigi, Gasbarrini, Antonio, De Marco, Rosanna, Piano, Salvatore, Nardelli, Silvia, Elia, Chiara, Roncadori, Andrea, Baldassarre, Maurizio, Bernardi, Mauro, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Caraceni, Paolo, Tufoni, Manuel, Zaccherini, Giacomo, Riggio, Oliviero, Angeli, Paolo, Alessandria, Carlo, Neri, Sergio, Foschi, Francesco G, Levantesi, Fabio, Airoldi, Aldo, Simone, Loredana, Svegliati-Baroni, Gianluca, Fagiuoli, Stefano, Laffi, Giacomo, Cozzolongo, Raffaele, Di Marco, Vito, Sangiovanni, Vincenzo, Morisco, Filomena, Toniutto, Pierluigi, Gasbarrini, Antonio, De Marco, Rosanna, Piano, Salvatore, Nardelli, Silvia, Elia, Chiara, Roncadori, Andrea, Baldassarre, Maurizio, Bernardi, Mauro, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

N/A

Published
2020

162. Primary HBB gene mutation severity and long‐term outcomes in a global cohort of β‐thalassaemia.

Author

Musallam, Khaled M., Vitrano, Angela, Meloni, Antonella, Addario Pollina, Sebastiano, Di Marco, Vito, Hussain Ansari, Saqib, Filosa, Aldo, Ricchi, Paolo, Ceci, Adriana, Daar, Shahina, Vlachaki, Efthymia, Singer, Sylvia T., Naserullah, Zaki A., Pepe, Alessia, Scondotto, Salvatore, Dardanoni, Gabriella, Karimi, Mehran, El‐Beshlawy, Amal, Hajipour, Mahmoud, and Bonifazi, Fedele

Subjects
GENETIC mutation, COMORBIDITY, GENOTYPES, CONFIDENCE intervals
Abstract

Summary: In β‐thalassaemia, the severity of inherited β‐globin gene mutations determines the severity of the clinical phenotype at presentation and subsequent transfusion requirements. However, data on associated long‐term outcomes remain limited. We analysed data from 2109 β‐thalassaemia patients with available genotypes in a global database. Genotype severity was grouped as β0/β0, β0/β+, β+/β+, β0/β++, β+/β++, and β++/β++. Patients were followed from birth until death or loss to follow‐up. The median follow‐up time was 34·1 years. Mortality and multiple morbidity outcomes were analyzed through five different stratification models of genotype severity groups. Interestingly, β0 and β+ mutations showed similar risk profiles. Upon adjustment for demographics and receipt of conventional therapy, patients with β0/β0, β0/β+, or β+/β+ had a 2·104‐increased risk of death [95% confidence interval (CI): 1·176–3·763, P = 0·011] and 2·956‐increased odds of multiple morbidity (95% CI: 2·310–3·784, P < 0·001) compared to patients in lower genotype severity groups. Cumulative survival estimates by age 65 years were 36·8% for this subgroup compared with 90·2% for patients in lower genotype severity groups (P < 0·001). Our study identified mortality and morbidity risk estimates across various genotype severity groups in patients with β‐thalassaemia and suggests inclusion of both β+ and β0 mutations in strata of greatest severity. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

163. First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.

Author

Cabibbo, Giuseppe, Reig, Maria, Celsa, Ciro, Torres, Ferran, Battaglia, Salvatore, Enea, Marco, Rizzo, Giacomo Emanuele Maria, Petta, Salvatore, Calvaruso, Vincenza, Di Marco, Vito, Craxì, Antonio, Singal, Amit G., Bruix, Jordi, and Cammà, Calogero

Subjects
ALTERNATIVE treatment for cancer, LIVER cancer, BEVACIZUMAB, CANCER treatment, IMMUNOTHERAPY, CLINICAL trials
Abstract

Introduction: Atezolizumab (ATEZO) plus bevacizumab (BEVA) represents the new standard of care for the treatment of advanced hepatocellular carcinoma (HCC). However, the choice of the second-line treatment after the failure of immunotherapy-based first-line remains elusive. Taking into account the weaknesses of the available evidence, we developed a simulation model based on available phase III randomized clinical trials (RCTs) to identify optimal risk/benefit sequential strategies. Methods: A Markov model was built to estimate the overall survival (OS) of sequential first- and second-line systemic treatments. Sequences starting with first-line ATEZO plus BEVA followed by 5 second-line treatments (sorafenib [SORA], lenvatinib [LENVA], regorafenib, cabozantinib, and ramucirumab) were compared. The probability of transition between states (initial treatment, cancer progression, and death) was derived from RCTs. Life-year gained (LYG) was the main outcome. Rates of severe adverse events (SAEs) (≥ grade 3) were calculated. The incremental safety-effectiveness ratio (ISER) was calculated as the difference in probability of SAEs divided by LYG between the 2 most effective sequences. Results: ATEZO plus BEVA followed by LENVA (median OS, 24 months) or SORA (median OS, 23 months) was the most effective sequence, producing a LYG of 0.50 and 0.42 year, respectively. ATEZO plus BEVA followed by SORA was the safest sequence (SAEs 63%). At a willingness-to-risk threshold of 10% of SAEs for LYG, ATEZO plus BEVA followed by second-line SORA was favored in 72% of cases, while at a threshold of 30% of SAEs for LYG, ATEZO plus BEVA followed by second-line LENVA was favored in 69% of cases. Conclusion: Our simulation model provides a strong rationale to support ongoing trials evaluating second-line tyrosine-kinase inhibitors after first-line ATEZO plus BEVA. Future evidence from ongoing RCTs and prospective real-world studies are needed to prove the net health benefit of sequential treatment options for advanced HCC. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

165. SAT535 - Correction and prevention of hyponatremia in patients with cirrhosis and ascites-post hoc analysis of the ANSWER study database

Author

Zaccherini, Giacomo, Baldassarre, Maurizio, Tufoni, Manuel, Riggio, Oliviero, Angeli, Paolo, Alessandria, Carlo, Neri, Sergio, Foschi, Francesco Giuseppe, Levantesi, Fabio, Airoldi, Aldo, Simone, Loredana, Svegiati-Baroni, Gianluca, Fagiuoli, Stefano, Laffi, Giacomo, Cozzolongo, Raffaele, Di Marco, Vito, Sangiovanni, Vincenzo, Morisco, Filomena, Toniutto, Pierluigi, Tortora, Annalisa, De Marco, Rosanna, Nardelli, Silvia, Piano, Salvatore, Elia, Chiara, Bernardi, Mauro, and Caraceni, Paolo

Published
2022
Full Text
View/download PDF

168. FRI384 - Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset

Author

Mangia, Alessandra, Fagiuoli, Stefano, Di Marco, Vito, Shafran, Stephen, Khalili, Mandana, Milligan, Scott, Papatheodoridis, George, Ouzan, Denis, Rosati, Silvia, Ramji, Alnoor, Teti, Elisabetta, Garcia-Retortillo, Montserrat, Pérez Hernández, Francisco Andrés, Wong, Alexander, Fraser, Chris, Rodriguez-Tajes, Sergio, Mutiloa, Elena Jimenèz, Morano Amado, Luis Enrique, O’Loan, Joss, Campanale, Francesca, Macedo, Guilherme, Milella, Michele, Brixko, Christian, Buti, Maria, Veloz, María Guerra, Ranieri, Roberto, Borgia, Sergio, Bascia, Annalisa, Fernandez Rodriguez, Conrado Manuel, Conway, Brian, de Lédinghen, Victor, Fenech, Mary, Ryan, Pablo, Maida, Ivana, Martins, Alexandra, Scherbakovsky, Stacey, Ntalla, Ioanna, Hernández, Candido, Vanstraelen, Kim, and Turnes, Juan

Published
2022
Full Text
View/download PDF

172. Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut‐Off Approach.

Author

Cristoferi, Laura, Calvaruso, Vincenza, Overi, Diletta, Viganò, Mauro, Rigamonti, Cristina, Degasperi, Elisabetta, Cardinale, Vincenzo, Labanca, Sara, Zucchini, Nicola, Fichera, Anna, Di Marco, Vito, Leutner, Monica, Venere, Rosanna, Picciotto, Antonino, Lucà, Martina, Mulinacci, Giacomo, Palermo, Andrea, Gerussi, Alessio, D'Amato, Daphne, and Elisabeth O'Donnell, Sarah

Published
2021
Full Text
View/download PDF

173. GEMS, a Genetic and Metabolic Staging Predicting the Outcome of Non-Alcoholic Fatty Liver Disease

Author

Pennisi, Grazia, primary, Pipitone, Rosaria Maria, additional, Enea, Marco, additional, Battaglia, Salvatore, additional, Di Marco, Vito, additional, Di Martino, Vincenzo, additional, Spatola, Federica, additional, Zito, Rossella, additional, Cammà, Calogero, additional, Craxì, Antonio, additional, Grimaudo, Stefania, additional, and Petta, Salvatore, additional

Published
2020
Full Text
View/download PDF

174. NR1H4 rs35724 G&gt;C Variant Modulates Liver Damage in Nonalcoholic Fatty Liver Disease

Author

Grimaudo, Stefania, primary, Dongiovanni, Paola, additional, Pihlajamäki, Jussi, additional, Eslam, Mohammed, additional, Yki-Järvinen, Hannele, additional, Pipitone, Rosaria Maria, additional, Baselli, Guido, additional, Cammà, Calogero, additional, Di Marco, Vito, additional, Longo, Miriam, additional, Pennisi, Grazia, additional, Prati, Daniele, additional, Zito, Rossella, additional, Fracanzani, Anna Ludovica, additional, Craxì, Antonio, additional, George, Jacob, additional, Romeo, Stefano, additional, Valenti, Luca, additional, and Petta, Salvatore, additional

Published
2020
Full Text
View/download PDF

175. Development of a Severity Score System for Thalassemia Syndromes

Author

Vitrano, Angela, primary, Meloni, Antonella, additional, Addario Pollina, Walter, additional, Karimi, Mehran, additional, El-Beshlawy, Amal, additional, Hajipour, Mahmoud, additional, Di Marco, Vito, additional, Ansari, Saqib Hussain, additional, Filosa, Aldo, additional, Ricchi, Paolo, additional, Ceci, Adriana, additional, Daar, Shahina, additional, Singer, Sylvia Titi Titi, additional, Borgio, J F, additional, Pepe, Alessia, additional, Scondotto, Salvatore, additional, Dardanoni, Gabriella, additional, Di Maggio, Rosario, additional, Sacco, Massimiliano, additional, Vichinsky, Elliott P., additional, and Maggio, Aurelio, additional

Published
2019
Full Text
View/download PDF

178. Update of the statements on biology and clinical impact of occult hepatitis B virus infection

Author

Raimondo, Giovanni, primary, Locarnini, Stephen, additional, Pollicino, Teresa, additional, Levrero, Massimo, additional, Zoulim, Fabien, additional, Lok, Anna S., additional, Allain, Jean-Pierre, additional, Berg, Thomas, additional, Bertoletti, Antonio, additional, Brunetto, Maurizia Rossana, additional, Bruno, Raffaele, additional, Chen, Ding-Shinn, additional, Coppola, Nicola, additional, Cornberg, Markus, additional, Craxì, Antonio, additional, Dandri, Maura, additional, Di Marco, Vito, additional, Ferrari, Carlo, additional, Gaeta, Giovanni Battista, additional, Glebe, Dieter, additional, Guidotti, Luca G., additional, Kramvis, Anna, additional, Lampertico, Pietro, additional, Li, Chengyao, additional, Liang, Jake, additional, Marzano, Alfredo, additional, Michalak, Thomas I., additional, Pawlotsky, Jean-Michel, additional, Prati, Daniele, additional, Puoti, Massimo, additional, Samuel, Didier, additional, Soriano, Vincent, additional, Squadrito, Giovanni, additional, Sureau, Camille, additional, Trepo, Christian, additional, and Yuen, Man-Fung, additional

Published
2019
Full Text
View/download PDF

179. NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients

Author

Bellocchi, Maria Concetta, primary, Aragri, Marianna, additional, Carioti, Luca, additional, Fabeni, Lavinia, additional, Pipitone, Rosaria Maria, additional, Brancaccio, Giuseppina, additional, Sorbo, Maria Chiara, additional, Barbaliscia, Silvia, additional, Di Maio, Velia Chiara, additional, Bronte, Fabrizio, additional, Grimaudo, Stefania, additional, Mazzucco, Walter, additional, Frigeri, Ferdinando, additional, Cantone, Marco, additional, Pinto, Antonio, additional, Perno, Carlo Federico, additional, Craxì, Antonio, additional, Gaeta, Giovanni Battista, additional, Di Marco, Vito, additional, and Ceccherini-Silberstein, Francesca, additional

Published
2019
Full Text
View/download PDF

180. Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience

Author

Alberti, Alfredo, primary, Angarano, Gioacchino, additional, Colombo, Massimo, additional, Craxì, Antonio, additional, Di Marco, Vito, additional, Di Perri, Giovanni, additional, Gaeta, Giovanni Battista, additional, Ippolito, Giuseppe, additional, Mangia, Alessandra, additional, and Pasqualetti, Patrizio, additional

Published
2019
Full Text
View/download PDF

181. Long-term course of interferon-treated chronic hepatitis C

Author

Cammà, Calogero, Di Marco, Vito, Lo Iacono, Oreste, Almasio, Piero, Giunta, Marco, Fuschi, Patrizia, Vaccaro, Alessandra, Fabiano, Carmelo, Magrin, Silvio, Di Stefano, Rosa, Bonura, Celestino, Pagliaro, Luigi, and Craxì, Antonio

Published
1998

184. Liver stiffness quantification in biopsyproven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography.

Author

Taibbi, Adele, Petta, Salvatore, Matranga, Domenica, Caruana, Giovanni, Cannella, Roberto, Busè, Gabriele, Di Marco, Vito, Midiri, Massimo, and Bartolotta, Tommaso Vincenzo

Subjects
NON-alcoholic fatty liver disease, SHEAR waves, ELASTOGRAPHY, REFERENCE values, RECEIVER operating characteristic curves
Abstract

Purpose: This study prospectively assessed the performance of liver stiffness measurements using point shear-wave elastography (p-SWE) in comparison with transient elastography (TE) in patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD). Methods: Fifty-six consecutive adult patients with a histological diagnosis of NAFLD prospectively underwent TE and p-SWE on the same day. The median of 10 measurements (SWE-10), the first five (SWE-5), and the first three (SWE-3) measurements were analyzed for p-SWE. Liver biopsy was considered as the reference standard for liver fibrosis grade. Receiver operating characteristic (ROC) curves and areas under the ROC curves (AUROCs) were calculated to assess the performance of TE and p-SWE for the diagnosis of significant (F2-F4) and advanced fibrosis (F3-F4). Results: Forty-six patients (27 men, 19 women; mean age, 54.7±9.1 years) had valid p-SWE and TE measurements. Twenty-seven patients (58.7%) had significant fibrosis and 18 (39.1%) had advanced fibrosis. For significant fibrosis, both SWE-10 (AUROC, 0.787; P=0.002) and SWE-5 (AUROC, 0.809; P=0.001) provided higher diagnostic performance than TE (AUROC, 0.719; P=0.016) and SWE-3 (AUROC, 0.714; P=0.021), albeit without statistical significance (P=0.301). For advanced fibrosis, SWE-5 showed higher diagnostic performance (AUROC, 0.809; P<0.001) than TE (AUROC, 0.799; P<0.001), SWE-10 (AUROC, 0.797; P<0.001), and SWE-3 (AUROC, 0.736; P=0.003), although the differences were not statistically significant (P=0.496). The optimal SWE-10 and SWE-5 cutoff values were =8.4 and =7.8 for significant fibrosis, and =9.1 and =8.8 for advanced fibrosis, respectively. Conclusion: TE and p-SWE showed similar performance for the diagnosis of significant and advanced fibrosis in NAFLD patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

188. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals

Author

Lleo, Ana, primary, Aglitti, Andrea, additional, Aghemo, Alessio, additional, Maisonneuve, Patrick, additional, Bruno, Savino, additional, Persico, Marcello, additional, Rendina, Maria, additional, Ciancio, Alessia, additional, Lampertico, Pietro, additional, Brunetto, Maurizia R., additional, Di Marco, Vito, additional, Zuin, Massimo, additional, Andreone, Pietro, additional, Villa, Erica, additional, Troshina, Giulia, additional, Degasperi, Elisabetta, additional, Coco, Barbara, additional, Calvaruso, Vincenza, additional, Giorgini, Alessia M., additional, Conti, Fabio, additional, Di Leo, Alfredo, additional, Marzi, Luca, additional, Boccaccio, Vincenzo, additional, Bollani, Simona, additional, and Colombo, Massimo, additional

Published
2019
Full Text
View/download PDF

189. Real life experiences in HCV management in 2018

Author

Viganò, Mauro, primary, Andreoni, Massimo, additional, Perno, Carlo Federico, additional, Craxì, Antonio, additional, Aghemo, Alessio, additional, Alberti, Alfredo, additional, Andreone, Pietro, additional, Babudieri, Sergio, additional, Bonora, Stefano, additional, Brunetto, Maurizia Rossana, additional, Bruno, Raffaele, additional, Bruno, Savino, additional, Calvaruso, Vincenza, additional, Caporaso, Nicola, additional, Cartabellotta, Fabio, additional, Ceccherini-Silberstein, Francesca, additional, Cento, Valeria, additional, Ciancio, Alessia, additional, Colombatto, Piero, additional, Coppola, Nicola, additional, Di Marco, Vito, additional, Di Perri, Giovanni, additional, Fagiuoli, Stefano, additional, Gaeta, Giovanni Battista, additional, Gasbarrini, Antonio, additional, Lampertico, Pietro, additional, Pellicelli, Adriano, additional, Prestileo, Tullio, additional, Puoti, Massimo, additional, Raimondo, Giovanni, additional, Rizzardini, Giuliano, additional, Taliani, Gloria, additional, and Zignego, Anna Linda, additional

Published
2019
Full Text
View/download PDF

190. PNPLA3 Rs738409 C&gt;G Variant Predicts Liver-Related Outcomes in Patients with Non-Alcoholic Fatty Liver Disease

Author

Grimaudo, Stefania, primary, Pipitone, Rosaria Maria, additional, Pennisi, Grazia, additional, Celsa, Ciro, additional, Cammà, Calogero, additional, Di Marco, Vito, additional, Boemi, Roberta, additional, Giannetti, Aurora, additional, Spatola, Federica, additional, Marchesini, Giulio, additional, Craxì, Antonio, additional, and Petta, Salvatore, additional

Published
2019
Full Text
View/download PDF

191. AISF position paper on HCV in immunocompromised patients

Author

Marzano, Alfredo, primary, Angelucci, Emanuele, additional, Astegiano, Marco, additional, Baratelli, Chiara, additional, Biancone, Luigi, additional, Bironzo, Paolo, additional, Brancaccio, Giuseppina, additional, Brunetto, Maurizia Rossana, additional, Bruno, Raffaele, additional, Burra, Patrizia, additional, Cabras, Maria Giuseppina, additional, Caraceni, Paolo, additional, Chialà, Claudia, additional, Clemente, Maria Grazia, additional, Colli, Agostino, additional, Daniele, Bruno, additional, De Gasperi, Elisabetta, additional, Di Marco, Vito, additional, Ditto, Maria Chiara, additional, Fagiuoli, Stefano, additional, Ferri, Clodoveo, additional, Gaeta, Giovanni Battista, additional, Grossi, Paolo Antonio, additional, Imperatrice, Barbara, additional, Lampertico, Pietro, additional, Macaluso, Fabio Salvatore, additional, Madonia, Salvatore, additional, Marignani, Massimo, additional, Mazzarelli, Chiara, additional, Mella, Alberto, additional, Missale, Gabriele, additional, Parisi, Simone, additional, Pasulo, Luisa, additional, Puoti, Massimo, additional, Rendina, Maria, additional, Ribaldone, Davide, additional, Rossi, Giuseppe, additional, Toniutto, Pierluigi, additional, Tucci, Alessandra, additional, Vajro, Pietro, additional, Viganò, Mauro, additional, Volpes, Riccardo, additional, and Zignego, Anna Linda, additional

Published
2019
Full Text
View/download PDF

192. Evidence for Three Distinct Classes of Phenotype Severity in Beta-Thalassaemia

Author

Maggio, Aurelio, primary, Vitrano, Angela, additional, Meloni, Antonella, additional, Pollina, Walter Addario, additional, Karimi, Mehran, additional, El-Beshlawy, Amal, additional, Hajipour, Mahmoud, additional, Di Marco, Vito, additional, Ansari, Saqib Hussain, additional, Filosa, Aldo, additional, Ricchi, Paolo, additional, Ceci, Adriana, additional, Daar, Shahina, additional, Singer, Sylvia Titi, additional, Naserullah, Zaki A., additional, Pepe, Alessia, additional, Scondotto, Salvatore, additional, Adekile, Kunle, additional, Bouesseau, Marie Charlotte, additional, Christou, Soteroula, additional, Dardanoni, Gabriella, additional, Fang, Jianpei, additional, Fucharoen, Suthat, additional, Hermine, Olivier, additional, Hishamshah, Ibrahim, additional, Moi, Paolo, additional, Al-Jarrash, Sana, additional, Pistoia, Laura, additional, Pitrolo, Lorella, additional, Rigano, Paolo, additional, Sacco, Massimiliano, additional, Shah, Farrukh, additional, Srivastava, Alok, additional, Viprakasit, Vip, additional, Yassin, Mahmoud, additional, and Vichinsky, Elliott, additional

Published
2019
Full Text
View/download PDF

193. A complication risk score to evaluate clinical severity of thalassaemia syndromes.

Author

Vitrano, Angela, Meloni, Antonella, Addario Pollina, Walter, Karimi, Mehran, El‐Beshlawy, Amal, Hajipour, Mahmoud, Di Marco, Vito, Hussain Ansari, Saqib, Filosa, Aldo, Ricchi, Paolo, Ceci, Adriana, Daar, Shahina, Titi Singer, Sylvia, Naserullah, Zaki A., Pepe, Alessia, Scondotto, Salvatore, Dardanoni, Gabriella, Bonifazi, Fedele, Vichinsky, Elliott, and Maggio, Aurelio

Subjects
RECEIVER operating characteristic curves, ALANINE aminotransferase, ASPARTATE aminotransferase
Abstract

Summary: The thalassaemia syndromes (TS) show different phenotype severity. Developing a reliable, practical and global tool to determine disease severity and tailor treatment would be of great value. Overall, 7910 patients were analysed with the aim of constructing a complication risk score (CoRS) to evaluate the probability of developing one or more complications. Nine independent variables were included in the investigation as predictors. Logistic regression models were used for Group A [transfusion‐dependent thalassaemia (TDT)], Group B [transfused non‐TDT (NTDT)] and Group C (non‐transfused NTDT). Statistically significant predictors included age (years), haemoglobin levels, hepatic transaminases [alanine aminotransferase (ALT) and aspartate aminotransferase] and left‐ventricular ejection fraction (LVEF) for Group A; age (years), age at first chelation (months), ALT and LVEF for Group B; and age (years), mean serum ferritin (SF) levels and LVEF for Group C. The area under the receiver operating characteristic curve was 84·5%, 82·1% and 80·0% for Groups A, Group B and Group C respectively, suggesting the models had good discrimination. Finally, the CoRS for each group was categorised into four risk classes (low, intermediate, high, and very high) using the centiles of its distribution. In conclusion, we have developed a CoRS for TS that can assist physicians in prospectively tailoring patients' treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

194. Aminopyrine breath test predicts liver‐related events and death in HCV‐related cirrhosis on SVR after DAA therapy.

Author

Petta, Salvatore, Rini, Francesca, Calvaruso, Vincenza, Cammà, Calogero, Ciminnisi, Stefania, Di Marco, Vito, Giannini, Edoardo G., Grimaudo, Stefania, Maria Pipitone, Rosaria, Craxì, Antonio, and Aghemo, Alessio

Subjects
BREATH tests, CIRRHOSIS of the liver, HEPATITIS C virus, HEPATIC encephalopathy, ANTIVIRAL agents
Abstract

Background & Aims: In patients with hepatitis C virus (HCV)‐related advanced cirrhosis, the effects of sustained virological response (SVR) by direct antiviral agents (DAAs) on decompensation and liver deaths are less clearcut, since up to 30% of patients do not improve, and no predictors of outcome have been identified. We used 13C‐aminopyrine breath test (ABT) to assess whether its changes can predict liver‐related outcomes after DAA treatment in patients with HCV cirrhosis. Methods: Fifty consecutive patients with HCV cirrhosis were enrolled. Patients were included if they had Child A cirrhosis at risk for decompensation – defined as Child A6 (N = 22, 44%) or previous decompensation (N = 7, 14%) – or Child B cirrhosis (N = 21, 42%) eligible for DAA‐based antiviral therapy. ABT was performed at baseline and 12 weeks after the end of antiviral therapy. Patients received sofosbuvir‐based regimens. Results: Aminopyrine breath test was available for all 50 patients at baseline. The 120' cumulative dose was directly associated at regression analysis only with albumin levels (P =.001). ABT was available at follow‐up week 12 for 41 patients (FUW12), all with SVR, and followed for a median of 25.2 months (range 12.2‐32.1 months). Lower Ʌ ABT – defined as changes of 120' cumulative dose from FUW12 to baseline – (HR 0.97, 95% CI 0.94‐0.99; P =.02) and FUW12 hepatic encephalopathy (HR 19.0, 95% CI 1.16‐310.3; P =.03) were the only independent predictors of liver events/death at multivariate Cox regression analysis. The AUC of Ʌ ABT was good (0.87, 95% CI 0.75‐0.97), with a delta ≥0% well discriminating patients at lower vs patients at higher risk of liver‐related events/death (P <.001). Conclusions: In patients with advanced HCV cirrhosis who achieve SVR with DAA, Ʌ ABT assists in assessing the residual likelihood of liver‐related events and deaths after viral cure. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

195. Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients

Author

Mazzola, Giovanni, primary, Adamoli, Lucia, additional, Calvaruso, Vincenza, additional, Macaluso, Fabio Salvatore, additional, Colletti, Pietro, additional, Mazzola, Sergio, additional, Cervo, Adriana, additional, Trizzino, Marcello, additional, Di Lorenzo, Francesco, additional, Iaria, Chiara, additional, Prestileo, Tullio, additional, Orlando, Ambrogio, additional, Di Marco, Vito, additional, and Cascio, Antonio, additional

Published
2018
Full Text
View/download PDF

196. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

Author

Calvaruso, Vincenza, primary, Cabibbo, Giuseppe, additional, Cacciola, Irene, additional, Petta, Salvatore, additional, Madonia, Salvatore, additional, Bellia, Alessandro, additional, Tinè, Fabio, additional, Distefano, Marco, additional, Licata, Anna, additional, Giannitrapani, Lydia, additional, Prestileo, Tullio, additional, Mazzola, Giovanni, additional, Di Rosolini, Maria Antonietta, additional, Larocca, Licia, additional, Bertino, Gaetano, additional, Digiacomo, Antonio, additional, Benanti, Francesco, additional, Guarneri, Luigi, additional, Averna, Alfonso, additional, Iacobello, Carmelo, additional, Magro, Antonio, additional, Scalisi, Ignazio, additional, Cartabellotta, Fabio, additional, Savalli, Francesca, additional, Barbara, Marco, additional, Davì, Antonio, additional, Russello, Maurizio, additional, Scifo, Gaetano, additional, Squadrito, Giovanni, additional, Cammà, Calogero, additional, Raimondo, Giovanni, additional, Craxì, Antonio, additional, Di Marco, Vito, additional, Craxì, A., additional, Di Marco, V., additional, Cammà, C., additional, Calvaruso, V., additional, Petta, S., additional, Cabbibbo, G., additional, Colletti, P., additional, Mazzola, G., additional, Cascio, A., additional, Montalto, G., additional, Licata, A., additional, Giannitrapani, L., additional, Prestileo, T., additional, Di Lorenzo, F., additional, Sanfilippo, A., additional, Ficalora, A., additional, Madonia, S., additional, Tinè, F., additional, Malizia, G., additional, Latteri, F., additional, Maida, M., additional, Cartabellotta, F., additional, Vassallo, R., additional, Cacciola, I., additional, Caccamo, G., additional, Maimone, S., additional, Saitta, C., additional, Squadrito, G., additional, Raimondo, G., additional, Mondello, L., additional, Smedile, A., additional, D’Andrea, S., additional, Bertino, G., additional, Ardiri, A.L., additional, Frazzetto, E., additional, Rigano, G., additional, Montineri, A., additional, Larocca, L.N., additional, Cacopardo, B., additional, Benanti, F., additional, Russello, M., additional, Benigno, R., additional, Bellia, A., additional, Iacobello, C., additional, Davì, A., additional, Di Rosolini, M.A., additional, Digiacomo, A., additional, Fuduli, G., additional, Scifo, G., additional, Distefano, M., additional, Portelli, V., additional, Savalli, F., additional, Scalici, I., additional, Gioia, G., additional, Magro, A., additional, Alaimo, G., additional, Alinovi, M.R., additional, Salvo, A., additional, Averna, A., additional, Lomonaco, F., additional, Guarneri, L., additional, Maffeo, F., additional, Falzone, E., additional, and Pulvirenti, F., additional

Published
2018
Full Text
View/download PDF

197. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

Author

Caraceni, Paolo, primary, Riggio, Oliviero, additional, Angeli, Paolo, additional, Alessandria, Carlo, additional, Neri, Sergio, additional, Foschi, Francesco G, additional, Levantesi, Fabio, additional, Airoldi, Aldo, additional, Boccia, Sergio, additional, Svegliati-Baroni, Gianluca, additional, Fagiuoli, Stefano, additional, Romanelli, Roberto G, additional, Cozzolongo, Raffaele, additional, Di Marco, Vito, additional, Sangiovanni, Vincenzo, additional, Morisco, Filomena, additional, Toniutto, Pierluigi, additional, Tortora, Annalisa, additional, De Marco, Rosanna, additional, Angelico, Mario, additional, Cacciola, Irene, additional, Elia, Gianfranco, additional, Federico, Alessandro, additional, Massironi, Sara, additional, Guarisco, Riccardo, additional, Galioto, Alessandra, additional, Ballardini, Giorgio, additional, Rendina, Maria, additional, Nardelli, Silvia, additional, Piano, Salvatore, additional, Elia, Chiara, additional, Prestianni, Loredana, additional, Cappa, Federica Mirici, additional, Cesarini, Lucia, additional, Simone, Loredana, additional, Pasquale, Chiara, additional, Cavallin, Marta, additional, Andrealli, Alida, additional, Fidone, Federica, additional, Ruggeri, Matteo, additional, Roncadori, Andrea, additional, Baldassarre, Maurizio, additional, Tufoni, Manuel, additional, Zaccherini, Giacomo, additional, Bernardi, Mauro, additional, Domenicali, Marco, additional, Giannone, Ferdinando A, additional, Merli, Manuela, additional, Gioia, Stefania, additional, Fasolato, Silvano, additional, Sticca, Antonietta, additional, Campion, Daniela, additional, Risso, Alessandro, additional, Saracco, Giorgio M, additional, Maiorca, Daniela, additional, Rizzotto, Agostino, additional, Lanzi, Arianna, additional, Neri, Elga, additional, Visani, Anna, additional, Mastroianni, Antonio, additional, Alberti, Alberto B, additional, Mazzarelli, Chiara, additional, Vangeli, Marcello, additional, Marzioni, Marco, additional, Capretti, Francesca, additional, Kostandini, Alba, additional, Magini, Giulia, additional, Colpani, Maria, additional, Laffi, Giacomo, additional, Gabbani, Tommaso, additional, Marsico, Maria, additional, Zappimbulso, Marianna, additional, Petruzzi, Josè, additional, Calvaruso, Vincenza, additional, Parrella, Giovanni, additional, Caporaso, Nicola, additional, Auriemma, Francesco, additional, Guarino, Maria, additional, Pugliese, Fabio, additional, Gasbarrini, Antonio, additional, Leo, Pietro, additional, De Leonardis, Francesco, additional, Pecchioli, Alessandra, additional, Rossi, Piera, additional, Raimondo, Giovanni, additional, Negri, Elisa, additional, Dallio, Marcello, additional, Loguercio, Carmelina, additional, Conte, Dario, additional, Celli, Natascia, additional, Bringiotti, Roberto, additional, Castellaneta, Nicola M, additional, and Salerno, Francesco, additional

Published
2018
Full Text
View/download PDF

200. Targeted Therapies in Hepatocellular Carcinoma

Author

BRONTE, Fabrizio, BRONTE, Giuseppe, CUSENZA, Stefania, FIORENTINO, Eugenio, Rolfo, C, CICERO, Giuseppe, BRONTE, Enrico, DI MARCO, Vito, FIRENZE, Alberto, Angarano, G, Fontana, T, RUSSO, Antonio, Bronte, F., Bronte, G., Cusenza, S., Fiorentino, E., Rolfo, C., Cicero, G., Bronte, E., DI MARCO, V., Firenze, A., Angarano, G., Fontana, T., and Russo, A.

Subjects
Niacinamide, Vascular Endothelial Growth Factor A, Carcinoma, Hepatocellular, Settore MED/06 - Oncologia Medica, Cirrhosis, hepatocellular carcinoma, liver disease, targeted therapies, Antineoplastic Agents, Biochemistry, Drug Discovery, Animals, Humans, Molecular Targeted Therapy, Biology, Protein Kinase Inhibitors, Pharmacology, Pharmacology. Therapy, Phenylurea Compounds, TOR Serine-Threonine Kinases, Liver Neoplasms, Organic Chemistry, Antibodies, Monoclonal, Sorafenib, digestive system diseases, ErbB Receptors, Chemistry, Liver, Molecular Medicine
Abstract

The onset of hepatocellular carcinoma (HCC) is related to the development of non-neoplastic liver disease, such as viral infections and cirrhosis. Even though patients with chronic liver diseases undergo clinical surveillance for early diagnosis of HCC, this cancer is often diagnosed in advanced stage. In this case locoregional treatment is not possible and systemic therapies are the best way to control it. Until now sorafenib, a Raf and multi-kinase inhibitor has been the best, choice to treat HCC systemically. It showed a survival benefit in multicenter phase III trials. However the proper patient setting to treat is not well defined, since the results in Child-Pugh B patients are conflicting. To date various new target drugs are under developed and other biological treatments normally indicated in other malignancies are under investigation also for HCC. These strategies aim to target the different biological pathways implicated in HCC development and progression. The target drugs studied in HCC include anti-VEGF and anti-EGFR monoclonal antibodies, tyrosine kinase inhibitors and mTOR inhibitors. The most important challenge is represented by the best integration of these drugs with standard treatments to achieve improvement in overall survival and quality of life.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results